Urdex

Urdex may be available in the countries listed below.

Ingredient matches for Urdex

Ursodeoxycholic Acid

Ursodeoxycholic Acid is reported as an ingredient of Urdex in the following countries:

• Japan

International Drug Name Search

Cepodem

Cepodem may be available in the countries listed below.

Ingredient matches for Cepodem

Cefpodoxime

Cefpodoxime proxetil (a derivative of Cefpodoxime) is reported as an ingredient of Cepodem in the following countries:

• Bahrain


• China


• India


• Myanmar


• Poland


• South Africa


• Sri Lanka

International Drug Name Search

Dojilon

Dojilon may be available in the countries listed below.

Ingredient matches for Dojilon

Prednisolone

Prednisolone 21-(disodium phosphate) (a derivative of Prednisolone) is reported as an ingredient of Dojilon in the following countries:

• Japan

International Drug Name Search

Detrol LA

See also: Generic Detrol

Detrol LA is a brand name of tolterodine, approved by the FDA in the following formulation(s):

DETROL LA (tolterodine tartrate - capsule, extended release; oral)

• 
  Manufacturer: PHARMACIA AND UPJOHN
  
  Approval date: December 22, 2000
  
  Strength(s): 2MG, 4MG ^[RLD]

Has a generic version of Detrol LA been approved?

No. There is currently no therapeutically equivalent version of Detrol LA available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Detrol LA. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  3,3-diphenylpropylamines and pharmaceutical compositions thereof
  Patent 5,382,600
  Issued: January 17, 1995
  Inventor(s): Jonsson; Nils A. & Sparf; Bengt A. & Mikiver; Lembit & Moses; Pinchas & Nilvebrant; Lisbet & Glas; Gunilla
  Assignee(s): Pharmacia Aktiebolag
  ##STR1## Novel 3,3-diphenylpropylamines of formula (I) wherein R.sup.1 signifies hydrogen or methyl, R.sup.2, R.sup.3 and R.sup.4 independently signify hydrogen, methyl, methoxy, hydroxy, carbamoyl, sulphanoyl or halogen, and X represents a tertiary amino group -NR.sup.5, R.sup.6, wherein R.sup.5 and R.sup.6 signify non-aromatic hydrocarbyl groups, which may be the same or different and which together contain at least three carbon atoms, and which may form a ring together with the amine nitrogen, their salts with physiologically acceptable acids and, when the compounds can be in the form of optical isomers, the racemic mixture and the individual enantiomers, their use as drugs, especially as anticholinergic agents, their use for preparing an anticholinergic drug, pharmaceutical compositions containing the novel amines, and methods for preparing the same.
  
  Patent expiration dates:
  
  
  • March 25, 2012
    
  
  
  
  • September 25, 2012
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Pharmaceutical formulation and its use
  Patent 6,630,162
  Issued: October 7, 2003
  Inventor(s): Lisbeth; Nilvebrant & Bengt; Hallen & Birgitta; Olsson & Jan; Strombom & Torkek; Gren & Anders; Ringberg & Martin; Wikberg
  Assignee(s): Pharmacia AB
  The invention relates to a pharmaceutical formulation containing tolterodine or a tolterodine-related compound, or a pharmacologically acceptable salt thereof, as active ingredient, in which the formulation exhibits a controlled in vitro release of the active ingredient in phosphate buffer at pH 6.8 of not less than about 80% after 18 hours, and after oral administration to a patient is capable of maintaining a substantially constant serum level of the active moiety or moieties for 24 hours. The invention also relates to the use of the pharmaceutical formulation for treating overactive bladder and gastrointestinal disorders.
  
  Patent expiration dates:
  
  
  • November 11, 2019
    
    ✓ 
    Patent use: TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.
    ✓ 
    Drug product
  
  
  
  • May 11, 2020
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Therapeutic formulation for administering tolterodine with controlled release
  Patent 6,770,295
  Issued: August 3, 2004
  Inventor(s): Bo; Kreilgård & Lene; Orup Jacobsen & Ulla; Hoeck & Helle; Kristensen & Torkel; Gren & Lisbeth; Nilvebrant & Anders; Ringberg & Martin; Wikberg & Bengt; Hallén & Birgitta; Olsson & Jan; Strömbom
  Assignee(s): Pharmacia AB
  The present invention is drawn to a method of treating an unstable or overactive urinary bladder by treating the patient with tolterodine or a tolterodine-related compound, or pharmaceutically acceptable salt thereof, with a controlled release formulation that maintains a substantially constant serum level of the active moiety or moieties for at least 24 hours. The present invention is further drawn to a formulation for the method.
  
  Patent expiration dates:
  
  
  • August 26, 2019
    
    ✓ 
    Patent use: TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.
    ✓ 
    Drug product
  
  
  
  • February 26, 2020
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Controlled release bead, a method of producing the same and multiple unit formulation comprising it
  Patent 6,911,217
  Issued: June 28, 2005
  Inventor(s): Gren; Torkel & Ringberg; Anders & Wikberg; Martin & Wald; Randy J.
  Assignee(s): Pharmacia AB
  A controlled release bead comprises: (i) a core unit of a substantially water-soluble or water-swellable inert material; (ii) a first layer on the core unit of a substantially water-insoluble polymer; (iii) a second layer covering the first layer and containing an active ingredient; and (iv) a third layer of polymer on the second layer effective for controlled release of the active ingredient, wherein the first layer is adapted to control water penetration into the core. A method of producing the controlled release bead is also disclosed.
  
  Patent expiration dates:
  
  
  • August 26, 2019
    
    ✓ 
    Patent use: TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.
    ✓ 
    Drug product
  
  
  
  • February 26, 2020
    
    ✓ 
    Patent use: TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.
    ✓ 
    Pediatric exclusivity
    ✓ 
    Drug product
  
  

See also...

• Detrol LA Extended-Release Capsules Consumer Information (Wolters Kluwer)
• Detrol LA Consumer Information (Cerner Multum)
• Detrol LA Advanced Consumer Information (Micromedex)
• Tolterodine Consumer Information (Wolters Kluwer)
• Tolterodine Extended-Release Capsules Consumer Information (Wolters Kluwer)
• Tolterodine Consumer Information (Cerner Multum)
• Tolterodine Advanced Consumer Information (Micromedex)
• Tolterodine Tartrate AHFS DI Monographs (ASHP)

Cortizone for Kids

In the US, Cortizone for Kids (hydrocortisone topical) is a member of the drug class topical steroids and is used to treat Anal Itching, Aphthous Stomatitis - Recurrent, Atopic Dermatitis, Dermatitis, Eczema, Gingivitis, Proctitis, Pruritus, Psoriasis, Seborrheic Dermatitis and Skin Rash.

US matches:

• Cortizone for Kids

Ingredient matches for Cortizone for Kids

Hydrocortisone

Hydrocortisone is reported as an ingredient of Cortizone for Kids in the following countries:

• United States

International Drug Name Search

Suppositoria Glycerini Galvex

Suppositoria Glycerini Galvex may be available in the countries listed below.

Ingredient matches for Suppositoria Glycerini Galvex

Glycerol

Glycerol is reported as an ingredient of Suppositoria Glycerini Galvex in the following countries:

• Slovakia

International Drug Name Search